Brief: Vir Biotechnology Q4 EPS USD -0.31
23/02/2026 22:14
Feb 23 (Reuters) - Vir Biotechnology Q4 revenue USD 64.1 million vs. IBES estimate USD 23.2 million. Q4 net income USD -42.9 million
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO